Skip to main content
Livermore
Livermore
ZHEN

UBS Group AG

SEC CIK
0001610520
Latest filing
Aug 13, 2026

RNTX holding history

Rein Therapeutics, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

RNTX overviewAll 13F holders of RNTXFull Q2 2026 holdings

Shares (Q2 2026)
57,410
Value
$59.7K
% of portfolio
<0.1%
Quarters held
20
Since Q1 2021
Holdings of RNTX by UBS Group AG, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 202657,410$59.7K<0.1%+56,386+5,506.4%AddedHolders
Q1 20261,024$1.33K<0.1%−8,492−89.2%ReducedHolders
Q4 20259,516$11.0K<0.1%+9,433+11,365.1%AddedHolders
Q3 202583$95<0.1%−15,618−99.5%ReducedHolders
Q2 202515,701$22.0K<0.1%+12,721+426.9%AddedHolders
Q1 20252,980$5.28K<0.1%−4,271−58.9%ReducedHolders
Q4 20247,251$16.7K<0.1%+7,251NewHolders
Q3 20240$00.0%−3,145−100.0%Sold outHolders
Q2 20243,145$8.71K<0.1%+3,052+3,281.7%AddedHolders
Q1 202493$617<0.1%−2,051−95.7%ReducedHolders
Q4 20232,144$6.54K<0.1%+2,144NewHolders
Q3 20230$00.0%−1,357−100.0%Sold outHolders
Q2 20231,357$2.43K<0.1%+1,257+1,257.0%AddedHolders
Q1 2023100$124<0.1%−3,212−97.0%ReducedHolders
Q4 20223,312$7.85K<0.1%+3,212+3,212.0%AddedConverted for a 1-for-20 splitHolders
Q3 20222,000$00.0%00.0%UnchangedHolders
Q2 20222,000$1.00K<0.1%−9,120−82.0%ReducedHolders
Q1 202211,120$6.00K<0.1%−12,248−52.4%ReducedHolders
Q4 202123,368$13.0K<0.1%+15,684+204.1%AddedHolders
Q3 20217,684$8.00K<0.1%−4,011−34.3%ReducedHolders
Q2 202111,695$15.0K<0.1%+9,519+437.5%AddedHolders
Q1 20212,176$3.00K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.